Get started
Work

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Year: 2008
Type: article
Study design: Clinical Trial
DOI: 10.1093/annonc/mdm600
Authors: J.E. Rosenberg, S. Halabi, B.L. Sanford, A.L. Himelstein, J.N. Atkins, R.J. Hohl, F. Millard, D.F. Bajorin, E.J. Small
Institutions: University of California, San Francisco, University of California San Francisco Medical Center, Duke University, Duke Medical Center, University of Iowa, University of California San Diego, Moores Cancer Center, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: bronze
Awards: WUMC Cancer and Leukemia Group B, G1486637521, G149288587, Cancer and Leukemia Group B, G192656225, G20154349, CANCER AND LEUKEMIA GROUP B, CANCER AND LEUKEMIA GROUP B, G2296793909, G260759372, G2647518335, Cancer and Leukemia Group B Statistical Center, University of Iowa CALGB Institutional Grant, G3255944410, Southeast Cancer Control Consortium, Inc, Cancer and Leukemia Group B, G3710026009, G4530377164, G4670716055, G4744150602, CANCER AND LEUKEMIA GROUP B, CANCER AND LEUKEMIA GROUP B, Delaware/Christiana Care Community Clinical Oncology Program, Cancer and Leukemia Group B, Hematology-Oncology Associates of Central New York CCOP, Cancer and Leukemia Group B - The Ohio State University, G877081928, G973482110
OpenAlex ID: W2114552883
FWCI: 7.378
Cites: 23
Cited by: 52
Related to: 10